Division of Nephrology, Department of Pediatrics, Seattle Children's Hospital and University of Washington, 4800 Sand Point Way NE, OC.9.830, Seattle, WA, 98105, USA.
Division of Pediatric Nephrology, University of Alabama at Birmingham, Birmingham, AL, USA.
Pediatr Nephrol. 2018 Jan;33(1):181-186. doi: 10.1007/s00467-017-3779-0. Epub 2017 Aug 19.
In neonates, the validation of urinary biomarkers to diagnose acute kidney injury is a rapidly evolving field. The neonatal population poses unique challenges when assessing the collection, storage, and processing of urinary samples for biomarker analysis. Given this, establishing optimal and consistent sample processing in this population for meaningful use in ongoing clinical trials is important.
Urine from a cohort of 19 hospitalized neonatal intensive care unit patients enrolled in the Preterm Erythropoietin Neuroprotection Trial (Clinical Trial NCT01378273) was collected for biomarker analysis by indirect techniques using Fisher-brand cotton balls placed in the diapers. Fourteen urinary biomarkers were measured using commercially available kits via electrochemiluminescence on multiarray plates and compared between paired samples processed with centrifugation prior to storage versus prior to analysis.
None of the biomarker concentrations differed between samples undergoing centrifugation prior to storage versus prior to analysis. The difference between samples was within 2% of the estimated concentration for the protein in 12 of 14 biomarkers (86%), and all paired biomarker concentrations were within 4%. The percentage error analysis did not show a difference between paired samples, with biomarker percentage errors smaller than the stated immunoassay coefficient of variance.
The urinary concentrations of biomarkers were comparable between paired samples, demonstrating that indirectly collected neonatal urine samples do not require centrifugation after collection and before storage. The ability to use routine urine collection and storage methods to obtain samples for subsequent quantitative immunoassay analysis should facilitate studies of newborns and young children.
在新生儿中,用于诊断急性肾损伤的尿生物标志物的验证是一个快速发展的领域。在评估用于生物标志物分析的尿样采集、储存和处理时,新生儿人群带来了独特的挑战。考虑到这一点,对于正在进行的临床试验,在该人群中建立最佳和一致的样本处理方法对于有意义的应用非常重要。
从参加早产儿促红细胞生成素神经保护试验(临床试验 NCT01378273)的 19 名住院新生儿重症监护病房患者的队列中收集尿液,用于生物标志物分析,方法是使用 Fisher 牌棉花球间接技术放置在尿布中。使用市售试剂盒通过多阵列板上的电化学发光测量了 14 种尿生物标志物,并比较了在储存前与分析前进行离心处理的配对样本之间的差异。
在储存前与分析前进行离心处理的样本之间,没有一种生物标志物浓度存在差异。在 14 种生物标志物中的 12 种(86%)中,12 种生物标志物中有 12 种的蛋白质估计浓度的差异在 2%以内,所有配对生物标志物浓度都在 4%以内。百分比误差分析表明,配对样本之间没有差异,生物标志物百分比误差小于免疫测定规定的变异系数。
配对样本中生物标志物的浓度具有可比性,表明间接收集的新生儿尿液样本在收集后和储存前不需要离心。使用常规尿液收集和储存方法获取后续定量免疫分析用样本的能力,应有助于新生儿和幼儿的研究。